HER2+ Breast Cancer
Latest News
Advertisement
Latest Videos
CME Content
Advertisement
More News
February 12, 2021 - The European Commission has granted marketing authorization to tucatinib for use in combination with trastuzumab and capecitabine in the treatment of adult patients with HER2-positive, locally advanced or metastatic breast cancer who have previously received at least 2 HER2-targeted regimens
Sequencing Therapy in R/R HER2+ MBC
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
Newly FDA Approved Therapies: R/R HER2+ MBC
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
Dennis J. Slamon, MD, PhD, discusses how his passion for medicine stemmed from a high school biology class, the struggle to develop trastuzumab as a viable drug in HER2-positive breast cancer, and the movie about his research that he didn’t want to see made.
Moving Metastatic Therapy to Early Stage Setting
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
Hormone Therapy in HER2+ Breast Cancer
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
Jane L. Meisel, MD, discusses sequencing considerations in the first- and second-line settings of HER2-positive breast cancer.
De-Escalation of Adjuvant Anti-HER2 Therapy and Chemo
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
Adjuvant Systemic Therapy Data Updates
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
Sara A. Hurvitz, MD, reflects on key pivotal trials and recent regulatory decisions that have propelled progress in metastatic HER2-positive breast cancer.
January 20, 2021 - The antibody-drug conjugate trastuzumab deruxtecan has been granted conditional approval in the European Union for use as a single agent in the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received 2 or more HER2-based regimens.
Adjuvant Systemic Therapy Decision Factors
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
HR-/HER2+ Early Stage Breast Cancer: Standards of Care
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
Refining Treatment Approaches for HER2+ Breast Cancer
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
A discussion on systemic treatment for HER2+ breast cancer and the impact of recent clinical trial data on decision making, including data discussed at the ESMO and SABCS 2020 Annual Meetings.
Sara A. Hurvitz, MD, discusses the expanding HER2-positive metastatic breast cancer treatment arsenal.
Adam M. Brufsky, MD, PhD, discusses the updated findings from the ExteNET trial, the role of TKIs in treating patients with brain metastases, and unanswered questions that future research efforts should aim to address.
Lecia V. Sequist, MD, MPH, discusses the importance of implementing broad molecular testing in lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pan-RAS Molecular Glue ERAS-0015 for Metastatic Pancreatic Adenocarcinoma
2
FDA Approves Zanidatamab-Based Regimens for First-Line HER2+ Locally Advanced or Metastatic Gastric Cancer
3
FDA Grants Priority Review to Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
4
European Commission Approves Sacituzumab Govitecan Plus Pembrolizumab for Frontline PD-L1+ mTNBC
5